Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K8 for GA
NCT06164587Phase 2Completed
- Sponsor
- Inflammasome Therapeutics
- Start
- Apr 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of kamuvudine-8 in geographic atrophy (GA), age-related macular degeneration (AMD), sponsored by Inflammasome Therapeutics. Started Apr 2024; status: completed.
02
Drugs
kamuvudine-8
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT06164587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06164587.